Cargando…
Daily Dosing for Bedaquiline in Patients with Tuberculosis
The bedaquiline regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults is a loading dose of 400 mg QD for 2 weeks followed by 200 mg thrice weekly (TIW) for 22 weeks. Most TB antibiotics administered with bedaquiline are given QD. Using pharmacokinetic simulations, we explo...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811417/ https://www.ncbi.nlm.nih.gov/pubmed/31451504 http://dx.doi.org/10.1128/AAC.00463-19 |
_version_ | 1783462470349750272 |
---|---|
author | Salinger, David H. Nedelman, Jerry R. Mendel, Carl Spigelman, Melvin Hermann, David J. |
author_facet | Salinger, David H. Nedelman, Jerry R. Mendel, Carl Spigelman, Melvin Hermann, David J. |
author_sort | Salinger, David H. |
collection | PubMed |
description | The bedaquiline regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults is a loading dose of 400 mg QD for 2 weeks followed by 200 mg thrice weekly (TIW) for 22 weeks. Most TB antibiotics administered with bedaquiline are given QD. Using pharmacokinetic simulations, we explored alternative QD bedaquiline regimens and determined that 200 mg QD for 8 weeks followed by 100 mg QD provides comparable exposures to the approved regimen. This simpler regimen is under clinical evaluation. |
format | Online Article Text |
id | pubmed-6811417 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-68114172019-11-07 Daily Dosing for Bedaquiline in Patients with Tuberculosis Salinger, David H. Nedelman, Jerry R. Mendel, Carl Spigelman, Melvin Hermann, David J. Antimicrob Agents Chemother Clinical Therapeutics The bedaquiline regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults is a loading dose of 400 mg QD for 2 weeks followed by 200 mg thrice weekly (TIW) for 22 weeks. Most TB antibiotics administered with bedaquiline are given QD. Using pharmacokinetic simulations, we explored alternative QD bedaquiline regimens and determined that 200 mg QD for 8 weeks followed by 100 mg QD provides comparable exposures to the approved regimen. This simpler regimen is under clinical evaluation. American Society for Microbiology 2019-10-22 /pmc/articles/PMC6811417/ /pubmed/31451504 http://dx.doi.org/10.1128/AAC.00463-19 Text en Copyright © 2019 Salinger et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Clinical Therapeutics Salinger, David H. Nedelman, Jerry R. Mendel, Carl Spigelman, Melvin Hermann, David J. Daily Dosing for Bedaquiline in Patients with Tuberculosis |
title | Daily Dosing for Bedaquiline in Patients with Tuberculosis |
title_full | Daily Dosing for Bedaquiline in Patients with Tuberculosis |
title_fullStr | Daily Dosing for Bedaquiline in Patients with Tuberculosis |
title_full_unstemmed | Daily Dosing for Bedaquiline in Patients with Tuberculosis |
title_short | Daily Dosing for Bedaquiline in Patients with Tuberculosis |
title_sort | daily dosing for bedaquiline in patients with tuberculosis |
topic | Clinical Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811417/ https://www.ncbi.nlm.nih.gov/pubmed/31451504 http://dx.doi.org/10.1128/AAC.00463-19 |
work_keys_str_mv | AT salingerdavidh dailydosingforbedaquilineinpatientswithtuberculosis AT nedelmanjerryr dailydosingforbedaquilineinpatientswithtuberculosis AT mendelcarl dailydosingforbedaquilineinpatientswithtuberculosis AT spigelmanmelvin dailydosingforbedaquilineinpatientswithtuberculosis AT hermanndavidj dailydosingforbedaquilineinpatientswithtuberculosis |